Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Medicenna Announces the Launch of a Marketed Public Offering of Securities

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

By The Northwire Desk — AI Analysis May 13, 2026 · 16:01 MDNA · 0.62 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics Corp. announced a marketed public offering of securities on May 13, 2026, with Bloom Burton Securities Inc. acting as sole agent.
  • The offering terms (securities type, price, size) are to be determined through negotiation, creating immediate uncertainty regarding dilution levels.
  • Proceeds are designated for clinical and regulatory development of MDNA11 and MDNA113, working capital, and general corporate purposes.
  • This follows the May 12 announcement of first patient dosing in the NEO-CYT study (MDNA11 in neoadjuvant melanoma).
  • Historical context shows cash position declining from $15.7M in Nov 2025 to $10.6M in Feb 2026, with runway projected only into Q3 2026.
  • The financing announcement coincides with the depletion of existing cash reserves, confirming a need for external capital before operations cease.
Material Impact
  • Dilution Risk: Public offerings are inherently dilutive to existing shareholders; without specific pricing details, the market must price in potential downside from equity issuance.
  • Cash Runway Confirmation: The timing validates concerns raised in February 2026 financials regarding cash depletion by mid-to-late 2026. This is not a surprise but confirms the necessity of capital raising to avoid distress.
  • Clinical Progress Offset: While the NEO-CYT dosing (May 12) is positive, it does not offset the negative sentiment of immediate dilution in a risk-averse market environment.
  • Stock Price Reaction: The stock has already declined significantly from $1.64 to $0.62 over the past six months, suggesting the market had anticipated this financing need. The news confirms the trajectory rather than altering it fundamentally.
  • No Strategic Investor: Unlike previous "Game Changer" criteria involving specific strategic investors (e.g., Sprott), this is a standard agency offering without named anchor investors, limiting upside potential from the capital raise itself.
MDNA · Price
Company Overview
  • Company: Medicenna Therapeutics Corp., a clinical-stage biopharmaceutical company focused on immunotherapy.
  • Flagship Asset (MDNA11): A long-acting, "beta-enhanced not-alpha" IL-2 Superkine designed to activate CD8+ T cells and NK cells while sparing regulatory T cells. Currently in Phase 1/2 ABILITY-1 trial for advanced solid tumors.
  • Secondary Asset (MDNA113): First-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional Superkine; preclinical data shows superior tolerability compared to competitors, IND filing expected H2 2026.
  • Third Asset (Bizaxofusp/MDNA55): IL-4 Empowered Superkine targeting recurrent glioblastoma; Phase 2b trial showed median OS of 13.6 months vs 7 months standard care.
  • Development Stage: Clinical trials ongoing for MDNA11 and Bizaxofusp; preclinical for MDNA113. No commercial revenue reported in provided data.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 19, 2026 · 07:00

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

Financings